Development of a melanoma-specific adenovirus

Molecular Therapy

Volumn 6, Issue 4, 2002, Pages 471-480

  McCart, J Andrea ^a   Wang, Zhong Hui ^a   Xu, Hui ^a   Hu, Yun ^a   Park, Bernard ^a   Alexander, H Richard ^a   Bartlett, David L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adenovirus; Cancer; Gene therapy; Melanoma; Tissue specific promoter; Tissue specific replication

Indexed keywords

ADENOVIRUS VECTOR; LUCIFERASE; PRODRUG; PURINE DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE; VIRUS PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; ENHANCER REGION; ENZYME ACTIVITY; GENE CONSTRUCT; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MELANOMA CELL; NONHUMAN; PROMOTER REGION; SUICIDE GENE; TISSUE SPECIFICITY; TRANSACTIVATION; TRANSGENE; VIRAL GENE THERAPY; VIRUS GENE; VIRUS REPLICATION;

ADENOVIRIDAE; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; MURINAE;

EID: 0036800504     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0692     Document Type: Article

References (23)

1. Zhang, W. W. (1999). Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 6: 113-138.
2. Bartlett, D. L., and McCart, J. A. (2000). Suicide gene therapy. In Biological Therapy of Cancer (S. Hellman, V. T. DeVita, and S. A. Rosenberg, Eds.), pp. 781-796. Lippincott, Philadelphia.
3. Park, B. J., et al. (1999). Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Hum. Gene Ther. 889-898.
4. Galanis, E., Vile, R., and Russell, S. J. (2001). Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors. Crit. Rev. Oncol. Hematol. 38: 177-192.
5. Doronin, K., et al. (2001). Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol. 75: 3314-3324.
6. Hallenbeck, P. L., et al. (1999). A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10: 1721-1733.
7. Kurihara, T., Brough, D. E., Kovesdi, I., and Kufe, D. W. (2000). Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 106: 763-771.
8. Rodriguez, R., et al. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57: 2559-2563.
9. Yu, D. C., Sakamoto, G. T., and Henderson, D. R. (1999). Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59: 1498-1504.
10. Hitt, M. M., and Graham, F. L. (1990). Adenovirus E1 A under the control of heterologous promoters: Wide variation in E1A expression levels has little effect on virus replication. Virology 179: 667-678.
11. Bergelson, J. M., et al. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323.
12. Gnant, M. F. X., Puhlmann, M., Alexander, H. R., Jr., and Bartlett, D. L. (1999). Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor specific gene expression and prolongation of survival in mice. Cancer Res. 59: 3396-3404.
13. Khuri, F. R., et al. (2000). A controlled trial of intratumoral ONHX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6: 879-886.
14. Bischoff, J. R, et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376.
15. Siders, W. M., Halloran, P. J., and Fenton, R. G. (1996). Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 56: 5638-5646.
16. Siders, W. M., Halloran, P. J., and Fenton, R. G. (1998). Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus. Cancer Gene Ther. 5: 281-291.
17. Wang, X., Freeman, M., and Seed, B. (1998). Free inverted terminal repeat ends are required for efficient generation of recombinant adenovirus vectors. In American Society of Gene Therapy-Program & Abstracts, p. 126a. Washington Convention Center, Seattle, WA.
18. Hemmi, S., Geertsen, R., Mezzacasa, A., Peter, I., and Dummer, R. (1998). The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum. Gene Ther. 9: 2363-2373.
19. Puhlmann, M., Gnant, M., Brown, C. K., Alexander, H. R., and Bartlett, D. L. (1999). Thymidine kinase deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor directed gene therapy. Hum. Gene Ther. 10: 649-657.
20. Gadi, V. K., et al. (2000). In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther. 7: 1738-1743.
21. Osborne, T. F., Gaynor, R. B., and Berk, A. J. (1982). The TATA homology and the mRNA 5′ untranslated sequence are not required for expression of essential adenovirus E1A functions. Cell 29: 139-148.
22. Toyoizumi, T., et al. (2001). Deletion of E1A promoter elements enhances specificity of CEA-driven oncolytic adenoviruses. Mol. Ther. 3: 5349.
23. Graham, F. L., and Prevec, L. (1995). Methods for construction of adenovirus vectors. Mol. Biotech. 3: 207-220.